Search Medical Condition
Please enter condition
Please choose location

Bellevue, Nebraska Clinical Trials

A listing of Bellevue, Nebraska clinical trials actively recruiting patient volunteers.

RESULTS

Found (211) clinical trials

Randomized Placebo-controlled Multi-dose Study Comparing Budesonide/Formoterol to Symbicort in Asthmatic Patients

This is a pivotal trial that will examine therapeutic equivalence of a new generic fixed-dose combination product containing Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult patients with chronic but stable asthma as defined in National Asthma Education and ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma

This is a 12-week, multicenter, open-label study to evaluate the relationship between ABS eMDPI and clinical asthma exacerbation (CAE) in adult patients at least 18 years of age with exacerbation-prone asthma. The ABS eMDPI dose will be 90 mcg, 1 to 2 inhalations every 4 hours as needed, but patient ...

Phase

0.0 miles

Learn More »

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

The purpose of the study is to evaluate efficacy, safety, and pharmacokinetics (PK) of oral Plecanatide 0.5, 1.0 and 1.5 mg tablets dosed once a day as compared to matching placebo, when administered for 8 weeks in adolescents with chronic idiopathic constipation. This study will consist of a 4-week screening ...

Phase

0.0 miles

Learn More »

Observational Study of Obstructive Lung Disease (NOVELTY)

The NOVELTY study is a multi-country, multicentre, observational, prospective, longitudinal cohort study which will include patients with a physician diagnosis, or suspected diagnosis, of asthma and/or COPD. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. All patients enrolled in the NOVELTY study ...

Phase N/A

0.4 miles

Learn More »

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal Paediatric Subjects With Asthma Over a Year

There is a regulatory requirement to evaluate the extent of reduction (if any) of growth velocity associated with inhaled corticosteroid (ICS) containing products that are to be administered to children, and to this end there is Food and Drug Administration (FDA) regulatory guidance. This is a randomised, single-blind (run-in period)/double-blind ...

Phase

2.97 miles

Learn More »

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller ...

Phase

2.97 miles

Learn More »

PALISADE Follow-on Study (ARC004)

This is an international, multicenter, open-label, 2-arm follow-on study of the safety, tolerability, and efficacy of AR101 in peanut-allergic individuals who have completed the ARC003 study. This study will explore alternative dosing regimens during extended maintenance with AR101.

Phase

2.97 miles

Learn More »

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

The primary objective is to assess the safety and tolerability of AR101 when used in a CODIT™ regimen for approximately 6 months in peanut-allergic children.

Phase

2.97 miles

Learn More »

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

The primary objective of the study is to evaluate the time to resolution of influenza symptoms in adults with acute uncomplicated seasonal influenza A following administration of VX-787, with and without concomitant oseltamivir.

Phase

5.77 miles

Learn More »

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes With a FRC Extension Period

The maximum duration for GLP1-RA patients will be approximately 29 weeks: an up to 2 week screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or 9 day post-treatment safety followup period. Maximum duration for FRC patients will be approximately 55 weeks: an up to ...

Phase

5.77 miles

Learn More »